New set-up for IT at Bayer

BayerBayer is transforming its IT function to further accelerate the digitalization of the company. Leading IT providers will take over standardized services, such as the provision of digital workplaces for employees or the global operation of IT infrastructure. Internally, the IT function will focus on differentiating solutions for Bayer's businesses. The realignment is part of the efficiency and structural measures that Bayer announced back in November 2018.

"We're not only looking to achieve savings but to use this opportunity to establish a new set-up for our IT function. The goal is to deliver new solutions in health and agriculture much faster," says Wolfgang Nickl, Chief Financial Officer and member of the Board of Management at Bayer. "The support of external partners is essential for Bayer - and that's why we have chosen leading providers that we are already working with," adds Daniel Hartert, Chief Information Officer at Bayer. The partners will take on around 950 IT employees (full-time equivalents) from Bayer in Germany. The following strategic partners have been selected:

  • Atos for Global Workplace Services and Security Operations
  • Capgemini for Business Intelligence Analytics and Controlling (BIAC), Enterprise Resource Planning (excluding HR), global IT Infrastructure, Service Integration, and Unified Communications & Collaboration
  • Cognizant for IT solutions in the areas of Research & Development, Product Supply and Marketing & Sales for the Crop Science Division
  • Tata Consultancy Services for IT solutions in the areas of Research & Development, Product Supply and Marketing & Sales for the Consumer Health and Pharmaceuticals divisions, the corporate functions and HR IT

The six-year contract can be extended by one year. The respective employees in Germany will be moving to the partners in the coming months. "Parting ways with so many employees is not easy. However, this change also comes with opportunities. We are convinced that our IT colleagues will have good development prospects with the specialized providers. The respective activities will not be continued at Bayer," says Hartert.

Internally, the Bayer IT function will be organized in agile teams that are closely linked to the businesses. The aim is to digitalize the whole value chain: from research and development to product supply, marketing and sales.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros.

Most Popular Now

AstraZeneca COVID-19 vaccine Vaxzevria authorised …

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisat...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companie...

Takeda announces approval of Moderna's COVID-19 va…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under...

Sanofi and GSK initiate global Phase 3 clinical ef…

Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recomb...

Sanofi and GSK COVID-19 vaccine candidate demonstr…

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who h...

European Commission approves Venclyxto-based combi…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidi...

Novartis reaches milestone delivery of 1 billion c…

Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was s...

COVID-19 mRNA vaccines are immunogenic in pregnant…

Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age ...

Why are some COVID-19 vaccines working better for …

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine. If there's one take-home message for the...

Rogue antibodies wreak havoc in severe COVID-19 ca…

The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in ...

New vaccine platform: 'Two-one replicon-and-VLP-mi…

To stop the current SARS-CoV-2 pandemic, vaccines of high quality, safety, and efficacy are required. Scientists of the Paul-Ehrlich-Institut and the Ludwig Maximilian Un...

COVID-19 monoclonal antibodies reduce risk of hosp…

Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer compl...